Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 109 clinical trials
Cryoablation Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

This early phase I trial studies the side effects and feasibility of cryoablation, atezolizumab, and nab-paclitaxel in treating patients with triple negative breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Cryosurgery, also known as cryoablation …

prognostic stage iv breast cancer ajcc v8
atezolizumab
tumor cells
monoclonal antibodies
HER2
  • 0 views
  • 19 Feb, 2024
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy.

HER2
adjuvant chemotherapy
tumor excision
taxane
adenocarcinoma
  • 0 views
  • 19 Feb, 2024
A Patient-centered Continuous and Interdisciplinary Shared Decision Making Approach for Breast Cancer Rehabilitation

Background: Breast cancer rehabilitation has gradually expanded from post-surgery rehabilitation to continuous rehabilitation including prehabilitation between cancer diagnosis and surgical treatment, post-surgery rehabilitation, and return-to-work/return-home interventions.

  • 0 views
  • 19 Feb, 2024
Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer

Interventional, randomised, prospective, monocentric study

vitamin d
HER2
rheumatism
lupus
arthritis
  • 0 views
  • 19 Feb, 2024
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.

HER2
epidermal growth factor
systemic therapy
measurable disease
erbb1
  • 0 views
  • 19 Feb, 2024
Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema

This trial studies how well the Remotivation Process in an occupational therapy program works in improving adherence to lymphedema treatment programs in patients with breast cancer-related lymphedema. Lymphedema treatment programs are well developed and effective, but adherence to these programs are an issue.

cancer
breast carcinoma
breast cancer
lymphedema
carcinoma
  • 0 views
  • 19 Feb, 2024
Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

This is a prospective, single site, randomized, double-blind Phase III clinical trial to evaluate the clinical value of Traditional Chinese Medicine in the adjuvant therapy of triple-negative breast cancer patients.

oestrogen receptor
HER2
triple-negative breast cancer
traditional chinese medicine
creatinine clearance rate
  • 0 views
  • 19 Feb, 2024
LYT-100 in Healthy Volunteers and BCRL

Part 3 is a trial of up to 6-months duration for safety, tolerability, PK, biomarkers and exploratory clinical assessments in breast carcinoma patients with secondary lymphoedema

cancer
reconstructive surgery
nipple reconstruction
HER2
breast cancer
  • 0 views
  • 19 Feb, 2024
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

cancer
palbociclib
growth factor
HER2
her2- breast cancer
  • 0 views
  • 19 Feb, 2024
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

HER2
fulvestrant
alopecia
gonadotropin
solid tumour
  • 0 views
  • 19 Feb, 2024